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Abstract
Background: MicroRNAs (miRNAs) are small noncoding RNAs that potentially play a critical role in tumorigenesis.
Mounting evidence indicates that one specific miRNA: miR-320b is down regulated in numerous human cancers,
including colorectal cancer (CRC); making the hypothesis that miR-320b may play a key role in tumorigenesis plausible.
However, its role in carcinogenesis remains poorly defined. The goal of this study is to better clarify the role of
miR-320b in tumor growth of CRC.
Methods: Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was conducted to detect the
expression of miR-320b in CRC tissues and 5 CRC cell lines. The effect of miR-320b on cell proliferation was analyzed
in vitro and in vivo. Furthermore, a luciferase reporter assay was performed to measure the target effects of miR-320b.
Lastly, the messenger RNA (mRNA) and protein levels of the gene c-MYC were measured in CRC cell lines and tissues
by qRT-PCR, and confirmed via Western blot and Immunohistochemical (IHC) staining.
Results: The results presented here showed that miR-320b expression was down regulated in both CRC tissues and
cells. Overexpression of miR-320b in CRC cells was statistically correlated with a decrease of cell growth in vitro and
in vivo, while c-MYC was identified as a target gene of miR-320b in CRC. Furthermore, it was found that up-regulation
of c-Myc can attenuate the effects induced by miR-320b.
Conclusions: Our identification of c-MYC as a target gene of miR-320b provides new insights into the pathophysiology
of CRC proliferation, and identifies miR-320b as a novel therapeutic target for the treatment of CRC.
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Background
Colorectal cancer (CRC) is one of the most common
cancers, and accounts for approximately 9.4 % of all cancer
cases worldwide. According to the International Agency for
Research on Cancer (IARC), approximately 1 million new
cases are detected each year [1, 2]. There has been con-
siderable effort devoted to investigating the biological
mechanisms responsible for promotion of CRC; how-
ever, the detailed mechanisms underlying CRC patho-
genesis remain elusive.
MicroRNAs (miRNAs) are a class of small RNAs
(~22 nucleotides) down regulates the expression of their
target genes through mRNA degradation or translational
inhibition [3, 4]. The target site of miRNA has been
considered to be the 3′ un-translated region (3′ UTR) of
mRNA. However, increasing evidence shows that miRNAs
may also bind the coding regions or the 5′ un-translated
region (5′ UTRs) [5, 6]. Mounting evidence indicates that
post-translational regulation of gene expression mediated
by miRNAs acts as either a tumor suppressor or an onco-
gene in CRC [7–11]. Several miRNAs found in CRC such
as miR-451, miR-34, miR-135, miR-122, let-7a, miR-143,
miR-17-92, miR-101, miR-126, miR-200, miR-203, miR-
183 and miR-21 have been shown to have an effect on cell
growth and apoptosis; as well as invasion and migration
[11]. Previous studies have shown that miR-320b is signifi-
cantly down regulated in several cancers including CRC
[12], glioblastoma [13], gastric cancer [14] and bladder
cancer [15]. Given that down regulation of miR-320b is
common in a number of cancers, it has been hypothesized
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In this study, we evaluated the miR-320b expression
levels in tumor tissues from 48 CRC patients and found
that miR-320b was significantly down regulated in these
tissues. Additionally, it was found that the overexpres-
sion of miR-320b in CRC cells was correlated with ob-
served decreases in cell growth both in vitro and in vivo.
This study also demonstrated that c-MYC was directly
targeted by miR-320b, and that overexpression of miR-
320b in CRC cells decreased both mRNA production, and
protein expression of c-MYC. These findings strongly
suggested that miR-320b inhibited proliferation of CRC
cells through an inhibition of c-MYC gene function, and
that increasing miR-320b expression levels may provide a
novel approach for CRC treatments.
Methods
Tissue samples and cell lines
A total of 48 CRC tissue samples and their adjacent
non-tumor tissues were obtained from Department of
Colorectal Surgery, Changhai Hospital (Shanghai, China)
for qRT-PCR analysis. All tissue samples were obtained
surgically and immediately snap frozen and stored in
liquid nitrogen until use. The study protocol was approved
by Shanghai Changhai Hospital Ethical Committee, and
written informed consent was obtained from all subjects
before the study was conducted. Additionally, five normal
colorectal tissues were obtained from non-cancer patients
by colonoscopy. For the in vitro experiments, cell lines
including HCT-116, SW-480, SW-620, LoVo and HEK293
were used and were purchased from American Type
Culture Collection (ATCC). SW-480 and SW-620 were
cultured in Leibovitz’s L-15 medium containing 10 % FBS.
HCT-116 and LoVo cells were cultured in Ham’s F12K
medium containing 10 % FBS, and HEK293 cells were cul-
tured in DMEM medium containing 10 % FBS. All cells
were maintained at 37 °C in a humidified atmosphere with
5 % CO2.
RNA quantification
Total RNA was isolated using a Trizol extraction kit (Life
Technologies, USA) according to the manufacturer’s
instructions. Purified mRNA and miRNAs were detected
by qRT-PCR assay using All-in-One miRNA qRT-PCR
Detection Kit (GeneCopoeia, USA). U6 small RNA was
used as an internal control for normalization and quantifi-
cation of miR-320b expression. As an internal control
β-actin was measured for normalization and quantifi-
cation of c-Myc expression.
Luciferase reporter assay
The luciferase reporter was constructed by cloning human
c-MYC cDNA sequence into pMIR-Report (Ambion,
Austin, USA). Wild type or mutant c-MYC mRNA frag-
ments were amplified and cloned into the luciferase
reporter via Spe I and Hind III sites. Luciferase reporter
assays were performed as following, HEK293 and SW-480
cells were plated in a 96-well plate and co-transfected with
50 nM single-stranded miRNA mimics, or negative control
oligonucleotides, with 10 ng of firefly luciferase reporter
and 3 ng of pRL-TK (Promega, USA) using the JetPRIME
reagent (Polyplus-transfection). Cells were harvested 48 h
after the transfection and analyzed using Dual-Luciferase
Reporter Assay System (Promega, Japan).
Oligonucleotide and plasmid transfection
RNA oligos were chemically synthesized and purified by
(Genepharma, China). Sense sequence of human miR-
320b mimics was 5’- AAA GCU GGG UUG AGA GGG
CAA -3’ and antisense sequence was 5’- UUG CCC
UCU CAA CCC AGC UUU U-3’. Negative control oli-
gonucleotides were 5’-AAU UCU CCG AAC GUG UCA
CTT-3’ and 5’-GUG ACA CGU UCG GAG AAU UTT-
3’. The transfections were performed with INTERFERin
reagent (Polyplus-transfection). The final concentration
of miRNA was found to be 50 nM.
To generate pGL3-c-MYC constructs, the coding DNA
sequence fragment of c-MYC was amplified and inserted
into the KpnI and XhoI sites of the pGL3 construct. All
constructs were verified by direct sequencing. Finally, the
transfections were conducted using INTERFERin reagent
(Polyplus-transfection, France). The final concentration of
plasmids was diluted to 100 ng.
MTT assay
To measure in vitro growth of CRC cells, the MTT assay
was used. A total of 5 × 103 cells were seeded into each
well of 96-well plates and transfected with miR-320b
mimics or negative control oligonucleotides at a final con-
centration of 50 nM respectively. On the day of measure-
ment, 100 μl of spent medium was replaced with an equal
volume of fresh medium containing 0.5 mg/ml MTT.
Plates were incubated at 37 °C for 4 h, then the medium
was replaced with 100 μl of DMSO (Sigma, USA), and
were then shaken at room temperature for 10 min. Ab-
sorbance was then measured at a wavelength of 570 nm.
Tumorigenicity assay in Non Obese Diabetic (NOD) mice
All mice were cared and maintained according to the
National Institute of Health Guide for the Care and Use of
Laboratory Animals, with the approval of the Scientific
Investigation Board of Second Military Medical University,
Shanghai. Cholesterol-conjugated miR-320b mimics and
negative control oligonucleotides transfected SW-480 cells
(1 × 106) were suspended in 150 μl PBS and then injected
subcutaneously into either side of the posterior flank of
the same Non obese diabetic (NOD) 6 week old mice.
Mice were examined every three days over a course of
4 weeks. Tumor volume (V) was monitored by measuring
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the length (L) and width (W) of the tumor with calipers
and was calculated with the formula V = (L ×W2) × 0.5.
Western blot
Protein from tissue and cells was separated in a 12 % SDS-
PAGE gel and transferred onto a nitrocellulose membrane
(Bio-Rad, Hercules, USA). The membrane was blocked
with 5 % non-fat milk and incubated with anti-c-Myc anti-
body, anti-Cyclin D1 (Santa Cruz, CA) or anti-β-actin anti-
body (Sigma, CA, USA). After being washed extensively, a
goat anti-mouse secondary antibody (Pierce, IL, USA) was
added to the system. The proteins were detected using ECL
reagents (Pierce).
Immunohistochemical (IHC) staining
Paraffin-embedded tissue sections were deparaffinized in
xylene and rehydrated in graded series of ethanol
followed by heat induced epitope retrieval in citrate buffer
(PH 6.0). Sections were incubated at 4 °C overnight with
monoclonal antibodies against c-Myc (Santa Cruz, CA)
and Ki-67 (Cell Signaling Technology, Danvers, MA).
Immunostaining was performed using ChemMate DAKO
EnVision Detection Kit, Peroxidase/DAB, Rabbit/Mouse
(code K 5007, DakoCytomation, Glostrup, Denmark) ac-
cording to the manufacturer’s instructions. Subsequently,
sections were counterstained with hematoxylin (Dako)
and mounted in dimethyl benzene.
Statistical analysis
All statistical analyses were carried out using the SPSS
16.0 statistical software package. Continuous variables
were expressed as mean ± SEM. Differences between
groups were calculated with Student’s t test. A two-tailed
P value test was used with a P value of < 0.05 considered
statistically significant.
Results
The expression of miR-320b is down regulated in CRC
In order to identify the role of miR-320b in CRC car-
cinogenesis, the expression of miR-320b in CRC samples
(patient details have been listed in Table 1) and cell lines
was analyzed. As shown in Fig. 1a, miR-320b was signifi-
cantly decreased in CRC tissues versus adjacent non-
tumor tissues. It was also shown that miR-320b was
down-regulated in 4 CRC cell lines, when compared with
5 normal colorectal tissues (Fig. 1b). These observations
suggest that miR-320b may be an oncosuppressor in CRC.
miR-320b inhibits CRC growth in vitro and in vivo
To investigate the effect of miR-320b on CRC prolifera-
tion, miR-320b mimics or negative control oligonucleo-
tides were transiently transfected into two human CRC
cell lines, HCT-116 and SW-480. Measurements of RNA
expression levels using qRT-PCR (primer sequences have
been listed in Table 2) showedd that transfection of
miR-320b mimics significantly increased its expression
in HCT-116 and SW-480 cells (Fig. 2a). In the cell
Table 1 Patients’ characteristics of clinical-pathologic features
Characteristics No. of patients (n = 48) Percent (%)







≧3≤ 3 6 12.5
>3 and ≤5 28 58.3
>5 14 29.2
Fig. 1 miR-320b is down-regulated in CRC samples and cell lines. a Expression of miR-320b was measured in 48 CRC and adjacent non-tumor tissues
by qRT-PCR. b The expression levels of miR-320b were further measured in 5 normal tissues and 4 CRC cell lines by qRT-PCR. Data analyzed
using Student’s t-test.*p < 0.05, **p < 0.01
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proliferation assay, restoration of miR-320b in HCT-116
and SW-480 cells resulted in a significant suppression of
cell proliferation. The proliferation rate was suppressed in
HCT-116 and SW-480 cells after transfection with miR-
320b, and the inhibitory efficiencies were 50.0 (P < 0.01)
and 37.5 % (P < 0.01), respectively (Fig. 2b).
Inhibition of cell growth in cancer cells is usually asso-
ciated with concomitant cell cycle arrest. Cell cycle
analysis was performed to determine whether the effect
of miR-320b on cell proliferation was due to cell cycle ar-
rest. Indeed, the result showed a G1 arrest, with 61.46 %
± 7.66 % of miR-320b-transfected cells in G0/G1 versus
43.51 % ± 5.59 % of control HCT-116 cells. Similar effects
of miR-320b were found in SW-480 cells, with 61.5 % ±
7.34 % of miR-320b-transfected cells in G0/G1 versus
41.41 % ± 5.35 % of control cells (Fig. 2c). These results
Table 2 All primers used in this study
Name Primer sequence
U6 F 5’ - GTGCTCGCTTCGGCAGCACATATAC -3’
U6 R 5’- AAAAATATGGAACGCTTCACGAATTTG -3’
β-actin F 5’-AGAGCTACGAGCTGCCTGAC-3’
β-actin R 5’-AGCACTGTGTTGGCGTACAG-3’
c-Myc (WT) F 5’-GGCTAGTGATGCCCCTCAACGTTAGCTT-3’
c-Myc (WT) R 5’-AAAAGCTT GTAGTCGAGGTCATAGTTCC-3’
c-Myc (MUT) F 5’-GGCTAGTGATCGGGGAGTTGGTTTCGATCACC-3’
c-Myc (MUT) R 5’-AAAAGCTT GTAGTCGAGGTCATAGTTCC-3’
c-Myc (pGL3) F 5’-AAGGTACC ATGCCCCTCAACGTTAGCTTCACC-3’
c-Myc (pGL3) R 5’-AACTCGAGTTACGCACAAGAGTTCCGTAGC-3’
miR-320b F 5’- AAAAGCTGGGTTGAGAGGGCAA-3’
Abbreviations: F forward primer, R reverse primer, WT wild type, MUT mutant
Fig. 2 miR-320b overexpression inhibits CRC cells growth in vitro. a miR-320b expression was quantified by qRT-PCR analysis 48 h. after transfection of
miR-320b mimics (miR-320b) and negative control oligonucleotides (NC) in HCT-116 and SW-480 cells. b HCT-116 or SW-480 cells were transfected with
miR-320b or NC. Cell proliferation was measured using the MTT assay after culturing for 72 h. c Cell-cycle distribution was analyzed by
FACS analysis. HCT-116 and SW-480 cells were transfected with miR-320b or NC. Nocodazole (25 ng/ml) was added 24 h after transfection
for another 16 h, then the supernatant was replaced by fresh medium for 6 h. Data analyzed using Student’s t-test.*p < 0.05, **p < 0.01
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demonstrated that the overexpression of miR-320b in-
hibits the growth of CRC cells.
To better understand the modulation of miR-320b in
tumorigenisis, we used an in vivo model to evaluate the
effect of tumorigenicity after overexpression of miR-320b.
Cholesterol-conjugated miR-320b mimics and negative
control oligonucleotides transfected SW-480 cells were
injected subcutaneously into either side of the posterior
flank of the same NOD mice. In this tumorigenicity assay
(n =3), when compared with negative control oligonucleo-
tides (n =3) transfectants, miR-320b transfected cells re-
vealed a significant reduction in the tumor size (Fig. 3a, b)
and cell proliferation (Fig. 3c), suggesting a potential tumor
suppressive effect of miR-320b expression.
Identification of c-Myc as miR-320b direct target in CRC
To confirm miR-320b regulation of the expression of
c-MYC gene, we first performed luciferase reporter as-
says in HEK293 and SW-480 cells. As shown in Fig. 4a
and b, transfection of miR-320b caused a significant
decrease in luciferase activity in cells transfected with
the reporter plasmid with wild type targeting sequence
of c-MYC mRNA but not reporter plasmid with mu-
tant sequence of c-MYC.
HCT-116 and SW-480 cells which demonstrated a
lower expression of miR-320b (Fig. 1b) were transfected
with miR-320b mimics or negative control oligonucleo-
tides, and c-MYC mRNA as well as protein levels were
examined by qRT-PCR and confirmed via western blot-
ting. The levels of c-MYC mRNA and protein were con-
sistently and substantially down regulated by miR-320b
(Fig. 4c, d). Moreover, c-MYC mRNA levels were signifi-
cantly increased in CRC tissues versus adjacent normal
tissues which agreed with previous report [16]. Consistent
with this finding, Fig. 4f showed a reversed correlation
between miR-320b expression levels and c-MYC mRNA
levels in CRC tissues(r = −0.545, P < 0.001). CRC tissues
with low miR-320b consistently showed much higher
c-MYC expression compared to normal tissues with
high levels of miR-320b, but lower c-MYC expression
(Fig. 4g). Taken together, our results demonstrated that
c-Myc was a direct target of miR-320b in CRC cells.
Restoration of miR-320b suppresses c-Myc-induced CRC
proliferation
This study has shown that overexpression of miR-320b
suppressed the proliferation of CRC cells, and c-Myc
was a direct target of miR-320b. We next explored the
Fig. 3 miR-320b overexpression inhibits CRC cells growth in vivo. a Photographs of dissected tumors from NOD mice 4 weeks after inoculation. b The
curve of tumor growth. c Detection of Ki-67 by IHC in dissected tumor tissues was performed 4 weeks after inoculation. Data analyzed using Student’s
t-test.*p < 0.05, **p < 0.01
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inhibitory effect of miR-320b on CRC cells’ viability. It
was found that c-Myc protein levels in HCT-116 and
SW-480 cells significantly increased as well as its target-
ing genes such as Cyclin D1(key factor in cell growth
regulation [17, 18]). At the mean time, restoration of the
miR-320b expression levels in HCT-116 and SW-480
cells showed a markedly inhibited expression of c-Myc
and Cyclin D1 (Fig. 5a). In line with these findings, miR-
320b significantly suppressed c-Myc-induced cell prolifer-
ation in HCT-116 and SW-480 cells (Fig. 5b). Together,
these results demonstrated that miR-320b could regulate
CRC cells growth through targeting c-Myc.
Fig. 4 miR-320b down-regulates c-Myc expression in CRC cells. a Wild-type (WT) and mutant (Mut) of putative miR-320b targeting sequences in
c-Myc mRNA. Mutant sequences were shown in bold type. b Analysis of luciferase activity. HEK293 and SW-480 cells were co-transfected with
miR-320b mimics (miR-320b) or negative control oligonucleotides (NC), pRL-TK and firefly luciferase reporter plasmid containing putative miR-320b
targeting sequences of c-Myc. c, d The endogenous c-Myc mRNA (c) and protein (d) levels were quantified 48 h. after transfection of (miR-320b) and
(NC) in HCT-116 and SW-480 cells. e Expression of c-Myc was measured in 48 CRC and adjacent non-tumor tissues by qRT-PCR. f A negative Spearman
correlation between miR-320b and c-Myc mRNA levels was found in CRC samples. g Analysis of c-Myc and miR-320b expression in the same CRC and
adjacent non-tumor tissue by IHC and qRT-PCR. Brown signal in IHC was considered as positive staining for c-Myc. Scale bar = 50 μm. Data analyzed
using Student’s t-test.*p < 0.05, **p < 0.01
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Discussion
In this study, we examined the expression profile of
miR-320b in CRC. Our results showed that miR-320b
was down-regulated in CRC tissues as well as in 2
human CRC cell lines, which was similar with previous
reports [12]. In addition, we identified c-Myc as a direct
and functional target of miR-320b in CRC cells. Overex-
pression of miR-320b in CRC cells significantly inhibited
the cell proliferation by down-regulating c-Myc.
The interest in understanding the role of miRNA in
cancer cells and carcinogenesis has grown rapidly, so
has the amount of studies in this field [9, 10]. There has
been reports showing that miR-320 is down regulated in
several tumor types [12–15], and one of miR-320 ‘s down-
stream effects was inhibiting cell proliferation by targeting
transferrin receptor 1 (CD71) in human leukemia cell line
HL-60 [19]. Additionally, it is known that miR-320 sup-
presses the stem cell like characteristics of prostate cancer
cells by down regulating the Wnt/beta-catenin signaling
pathway [20].
Deregulation of miRNAs has been indicated to be
heavily involved in tumorigenesis and tumor development
[10, 21, 22]. Our results showed that miR-320b was down-
regulated in CRC, which prompted us to further investigate
the role of miR-320b in CRC cells. In order to explore the
underlying mechanisms of the silenced miR-320b in CRC,
the CRC pathogenesis-related target genes were further an-
alyzed. In a recent study, 18,000 high-confidence miRNA-
mRNA interactions in HEK 293 cells by CLASH were
reported [23]. However, it remains unclear whether these
miRNA pairings also exist in CRC cells. The CLASH data
showed that 72 genes were targeted by miR-320b. Among
these genes, we focused on c-MYC, a central component of
the MAPK/ERK pathway, which is involved in many
cellular processes including cell growth, cell differenti-
ation, apoptosis and other cellular functions [17]. From
the CLASH data in HEK293 cells, the potential target-
ing sequence for miR-320b with a calculated energy of
−23.1 kcal/mol is within the protein coding region of c-
Myc mRNA from 556 to 603 [23]. This targeting mode is
similar to miR-185-3p (a potential target sequence in the
protein coding region of c-Myc mRNA [24]), while distinct
from other c-Myc targeting miRNAs such as miR-145, let-
7a, miR-24(target sites in 3’UTR of c-Myc [25–27]). How-
ever, the role of miR-320b in CRC is not fully understood
because of the lack of target gene information.
Fig. 5 miR-320b inhibits the proliferation of CRC cells by targeting c-Myc. a HCT-116 and SW-480 cells were transfected with miR-320b and/or
pGL3-c-Myc, 48 h. later the expressions of c-Myc and Cyclin D1 were analyzed via western blotting. b HCT-116 andSW-480 cells were transfected
with miR-320b and/or pGL3-c-Myc, and cell proliferation was measured by by MTT assay at 72 h. after transfection. Data analyzed using Student’s
t-test.*p < 0.05, **p < 0.01
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Our results demonstrated that c-Myc was directly
targeted by miR-320b in CRC cells. Overexpression of
miR-320b in CRC cells decreased both mRNA and pro-
tein levels of c-MYC, a finding that is consistent with a
previous work reporting a negative correlation of miR-
320b with various genes including c-MYC in CRC [28].
Our results suggest that miR-320b is a candidate tumor
suppressor in the pathogenesis of CRC.
c-MYC is a node gene in multiple pathways, and most of
its target genes including CCND1 are crucial for cell
growth, proliferation and development [29–31]. As a regu-
lator gene, c-MYC is carefully managed at different levels
[32]. Recent studies have shown that the deregulation of
miRNAs is responsible for high levels of c-Myc in many
cancers. Several miRNA are known to be regulators of
c-Myc in various different cancers including miR-24 in
leukemia [26], miR-145 in oral squamous cell carcin-
oma [25], let-7a in burkitt lymphoma [27], miR-34a in
renal cell carcinoma [33] and miR-185-3p in CRC [24].
In this study, c-Myc was identified to be directly tar-
geted, and regulated by miR-320b in CRC cells. Our
results agreed with the viewpoint that a single mRNA
molecule can been regulated by multiple miRNA genes
in different cells [34, 35].
Conclusions
We conclude that miR-320b is frequently down regulated
in CRC cell lines and clinical samples. Our data demon-
strated that c-Myc was directly targeted and regulated by
miR-320b, and that overexpression of miR-320b signifi-
cantly inhibited CRC cells proliferation through regulating
c-Myc. Our identification of c-Myc as a target of miR-
320b provides new insights into the pathophysiology of
CRC proliferation and identifies miR-320b as a novel
therapeutic targets for the treatment of CRC.
Abbreviation
CRC: Colorectal cancer; mRNA: Messenger RNA; qRT-PCR: Quantitative real-time
PCR; miR-320b: MicroRNA-320b; IHC: Immunohistochemistry;
CLASH: Crosslinking, ligation, and sequencing of hybrids.
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